It's on page 8 of the annual report - https://ir.avitamedical.com/static-files/9fd10644-e4fd-47fd-8c6d-e457b91ca9c5
Rejuvenation
We believe that reversing aging at a cellular level has the potential to impact rejuvenation by driving functional changes to skin cells. This will be significantly different from existing products, such as cosmeceuticals that supplement proteins to cells, and surgical approaches that do not alter cellular stat but alter tissue morphology. An approach for molecular reversal of the underlying defects resulting in aging could have a profound effect on rejuvenation.
In November 2020, AVITA Medical announced a preclinical research agreement with the Houston Methodist Research Institute (“HMRI”) to explore molecular reversal of cellular aging through a novel cell suspension delivery system. AVITA Medical retains the option to exclusively license HMRI’s patented technology as well as the right of first negotiations to HMRI’s technologies emerging from the partnership for further development and commercialization.
HMRI is a compelling partner for this work. Dr. John Cooke and his team have developed a novel, patented approach of telomerase reverse transcriptase delivery to reverse cellular aging and have been widely recognized as leaders in this space with multiple peer reviewed publications, grants, and awards. Further, HMRI has a strong program in translational medicine, including the Center for Rapid Device Translation that supports preclinical testing and GLP environments which could enable rapid translation from research into clinical trials.
In collaboration with HMRI, skin cells harvested using the RECELL Device have been molecularly reverse-aged, and used to regenerate skin in a mouse model, thereby establishing proof of concept. Work is ongoing to characterize the tissue to identify functional attributes associated with rejuvenated skin.
Is that the part you were after?
The commentary on it in the investor briefing (around the 36min mark) sounded promising to me. Presumably, improved healing could be used for all current and future indications, plus would provide additional patent protection. Obviously, it will take time for trials and approvals but I'd be very happy if this is progressing behind the scenes.
- Forums
- ASX - By Stock
- The near term future
It's on page 8 of the annual report -...
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVH (ASX) to my watchlist
|
|||||
Last
$2.66 |
Change
-0.060(2.21%) |
Mkt cap ! $184.2M |
Open | High | Low | Value | Volume |
$2.73 | $2.73 | $2.66 | $321.5K | 120.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1499 | $2.66 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.70 | 50 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 2.680 |
2 | 11148 | 2.650 |
1 | 11049 | 2.640 |
1 | 2000 | 2.630 |
2 | 10300 | 2.620 |
Price($) | Vol. | No. |
---|---|---|
2.530 | 421 | 4 |
2.700 | 50 | 1 |
2.710 | 325 | 1 |
2.750 | 265 | 1 |
2.770 | 1367 | 2 |
Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online